Quantcast
Home > Quotes > NBIX
NBIX

Neurocrine Biosciences, Inc. Common Stock (NBIX) Quote & Summary Data

$73.83
*  
11.93
13.91%
Get NBIX Alerts
*Delayed - data as of Dec. 12, 2018  -  Find a broker to begin trading NBIX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
131
Today's High / Low
$ 74.18 / $ 64.72
Share Volume
13,083,465
50 Day Avg. Daily Volume
874,692
Previous Close
$ 85.76
52 Week High / Low
$ 126.98 / $ 68.22
Market Cap
6,695,065,497
P/E Ratio
1,476.6
Forward P/E (1y)
451.37
Earnings Per Share (EPS)
$ 0.05
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.36

Intraday Chart

Shares Traded

Share Volume:
13,083,465
50 Day Avg. Daily Volume:
874,692

P/E Ratio

P/E Ratio:
1,476.6
Forward P/E (1y):
451.37
Earnings Per Share (EPS):
$ 0.05

Trading Range

The current last sale of $73.83 is 8.22% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 74.18 $ 126.98
 Low: $ 64.72 $ 68.22

ETFs with NBIX as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
5.07% Invesco Dynamic Biotech & Genome ETF (PBE) -9.32 (-15.64%)
2.27% Principal Healthcare Innovators Index ETF (BTEC) -4.06 (-11.72%)
0.01% Vanguard Small-Cap Growth ETF (VBK) -23.34 (-12.72%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We were originally incorporated in California in January 1992 and were reincorporated in Delaware in May 1996. We are a company focused on discovering, developing, and commercializing innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through our novel R&D platform, focused on neurological and endocrine based diseases and disorders. Our portfolio of products and product candidates is led by INGREZZA® (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders which was approved by the U.S. Food and Drug Administration (FDA) on April 11, 2017 for the treatment of tardive dyskinesia (TD). Our three lead late-stage clinical programs are INGREZZA (valbenazine) for Tourette syndrome, elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc.  ... More ...  


Risk Grade

Where does NBIX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 67.61
Open Date:
Dec. 12, 2018
Close Price:
$ 85.76
Close Date:
Dec. 12, 2018

Consensus Recommendation

Analyst Info